The Israeli-owned device maker's China facility begins producing its Alma Rejuve platform, reducing supply-chain risk and supporting regional expansion.
Sisram Medical announced that its China manufacturing facility has commenced operations, with the first Alma Rejuve units rolling off the line. Alma Rejuve is a multipurpose energy platform combining RF microneedling, ultrasound, and other modalities for skin tightening and resurfacing.
Local manufacturing in China reduces supply-chain vulnerability and lowers landed cost for regional distribution—critical as aesthetic device demand accelerates in Asia-Pacific markets. For U.S. and European practices, this signals Sisram's commitment to scale production and potentially improve delivery timelines and pricing competitiveness against InMode, Cutera, and other established players.
China facility begins Alma Rejuve production; supply-chain localization reduces cost and delivery risk.
The move also suggests Sisram is hedging against tariff and logistics pressures affecting device imports. Practices should monitor whether localized production translates to improved availability or pricing in their markets over the next 12–18 months.
Source: original report ↗
Frequently asked questions
What is Alma Rejuve and what does it do?
Alma Rejuve is a multipurpose energy platform that combines RF microneedling, ultrasound, and other modalities for skin tightening and resurfacing. It's designed to address multiple aesthetic concerns in a single device, making it versatile for various treatment protocols.
Will Alma Rejuve prices drop due to China manufacturing?
Local manufacturing in China reduces landed costs and supply-chain vulnerability, which could improve pricing competitiveness over the next 12–18 months. However, actual price reductions will depend on how Sisram passes savings to regional and international markets.
How does Sisram's China facility affect device delivery times?
Localized production in China is expected to potentially improve delivery timelines for Asia-Pacific practices and may reduce wait times globally by decreasing import logistics and tariff pressures. Practices should monitor availability improvements over the coming year.
Is Alma Rejuve now only manufactured in China?
The announcement confirms that Sisram's China facility has begun producing Alma Rejuve units, but it does not specify whether this is the sole manufacturing location or if production continues elsewhere. Practices should contact Sisram directly for complete manufacturing details.
How does Sisram's localized production compare to InMode and Cutera?
Sisram's China manufacturing move positions it to compete more aggressively on pricing and delivery against established players like InMode and Cutera, particularly in Asia-Pacific markets where aesthetic device demand is accelerating. This localization strategy reduces supply-chain risk and improves regional distribution efficiency.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
